Published in J Hypertens on March 01, 2002
Relationship between left ventricular hypertrophy, hypertensive retinopathy, microalbuminuria and echocardiographic modalities in newly diagnosed hypertensive patients. Int J Cardiovasc Imaging (2010) 0.84
Cardiovascular and Renal Links along the Cardiorenal Continuum. Int J Nephrol (2011) 0.78
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet (2010) 6.36
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94
Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med (2002) 5.72
Management of hypertension: summary of NICE guidance. BMJ (2011) 5.60
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet (2011) 4.12
Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension (2009) 3.93
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens (2006) 3.29
Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens (2005) 3.15
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension (2007) 2.94
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Essential hypertension. Lancet (2007) 2.63
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. J Hypertens (2004) 2.50
Added impact of obesity and insulin resistance in nocturnal blood pressure elevation in children and adolescents. Hypertension (2008) 2.31
ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens (2012) 2.24
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care (2013) 2.07
VALUE and supremacy of blood pressure control for cardiovascular protection. J Hypertens (2004) 2.05
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension (2012) 2.02
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Carotid-femoral pulse wave velocity assessment by two different methods: implications for risk assessment. J Hypertens (2015) 1.98
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens (2007) 1.86
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation (2011) 1.77
Microvascular brain damage with aging and hypertension: pathophysiological consideration and clinical implications. J Hypertens (2011) 1.76
Blood pressure and obesity exert independent influences on pulse wave velocity in youth. Hypertension (2012) 1.70
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Influence of concurrent obesity and low birth weight on blood pressure phenotype in youth. Hypertension (2009) 1.64
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int (2012) 1.63
Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension (2005) 1.61
Drug treatment of hypertension. BMJ (2003) 1.59
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Resistant hypertension. BMJ (2012) 1.58
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens (2011) 1.57
The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation. J Hypertens (2002) 1.54
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
Predicting out-of-office blood pressure level using repeated measurements in the clinic: an observational cohort study. J Hypertens (2014) 1.53
Associations of birth weight and postnatal weight gain with cardiometabolic risk parameters at 5 years of age. Hypertension (2014) 1.52
Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. J Hypertens (2012) 1.49
RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection. J Immunol (2005) 1.48
Patients' experiences of self-monitoring blood pressure and self-titration of medication: the TASMINH2 trial qualitative study. Br J Gen Pract (2012) 1.44
2016 European Guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed) (2016) 1.42
Updated national and international hypertension guidelines: a review of current recommendations. Drugs (2014) 1.41
Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment. J Hypertens (2013) 1.39
High blood pressure in young people and premature death. BMJ (2011) 1.38
[Renal function as a prognostic marker of mortality in heart failure]. Med Clin (Barc) (2009) 1.38
Pulse wave analysis and hypertension: evangelism versus scepticism. J Hypertens (2004) 1.37
Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J (2008) 1.35
Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation (2013) 1.32
NICE hypertension guideline 2011: evidence based evolution. BMJ (2012) 1.28
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol (2012) 1.28
Blood pressure variables and cardiovascular risk: new findings from ADVANCE. Hypertension (2009) 1.22
Transient bacteremia induced by toothbrushing a comparison of the Sonicare toothbrush with a conventional toothbrush. Pediatr Dent (2002) 1.22
Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int (2009) 1.16
Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ Res (2007) 1.16
"Endogenous adjuvant" activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum (2006) 1.14
Galectin-1 interacts with beta-1 subunit of integrin. Biochem Biophys Res Commun (2003) 1.07
Treating hypertension: it is not how you start but where you end that matters. J Hypertens (2003) 1.07
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol (2013) 1.05
The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens (2005) 1.00
Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia (2014) 0.99
Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens (2013) 0.94
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens (2004) 0.94
The impact of the degree of obesity on the discrepancies between office and ambulatory blood pressure values in youth. J Hypertens (2006) 0.93
Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens (2012) 0.93
What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention (2014) 0.92
Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PLoS One (2012) 0.92
Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc (2012) 0.92
European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. J Hypertens (2009) 0.91
Central aortic pressure and clinical outcomes. J Hypertens (2009) 0.91
Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv (2013) 0.91
Patient self-monitoring of blood pressure and self-titration of medication in primary care: the TASMINH2 trial qualitative study of health professionals' experiences. Br J Gen Pract (2013) 0.91
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90
Parental Human Papillomavirus Vaccine Survey (PHPVS): nurse-led instrument development and psychometric testing for use in research and primary care screening. J Nurs Meas (2013) 0.90
Inadequate cytoplasmic antioxidant enzymes response contributes to the oxidative stress in human hypertension. Am J Hypertens (2007) 0.88
Reduced glomerular filtration rate in pre-dialysis non-diabetic chronic kidney disease patients is associated with impaired baroreceptor sensitivity and reduced vascular compliance. Clin Sci (Lond) (2006) 0.87
Protocol for a randomised controlled trial of telemonitoring and self-management in the control of hypertension: telemonitoring and self-management in hypertension. [ISRCTN17585681]. BMC Cardiovasc Disord (2009) 0.87
Transient receptor potential vanilloid 1 agonists modulate hippocampal CA1 LTP via the GABAergic system. Neuropharmacology (2011) 0.86
Xanthine oxidoreductase polymorphisms: influence in blood pressure and oxidative stress levels. Pharmacogenet Genomics (2007) 0.86
Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol (2008) 0.86
A novel foundation-year-two post in academic medicine. J R Soc Med (2005) 0.86